Literature DB >> 6488556

Dihydropyrimidine dehydrogenase deficiency leading to thymine-uraciluria. An inborn error of pyrimidine metabolism.

R Berger, S A Stoker-de Vries, S K Wadman, M Duran, F A Beemer, P K de Bree, J J Weits-Binnerts, T J Penders, J K van der Woude.   

Abstract

Three unrelated patients with excessive thymine-uraciluria due to dihydropyrimidine dehydrogenase deficiency are described. Excretory values (mmol/g creatinine) were: uracil 2.0-10.5, thymine 2.3-7.5, 5-hydroxymethyluracil 0.2-0.9. Orally administered (index patient) uracil and thymine were excreted for the greater part whilst dihydrouracil and S-dihydrothymine were mainly metabolised. Dihydropyrimidine dehydrogenase activities (nmol X h-1 X mg-1 protein) in leucocytes were 0.04, 0.01 and less than 0.01 in the patients, 0.31-1.66 in their parents, and 1.01-4.46 in controls (n = 4). The patients presented with a non-specific clinical picture of cerebral dysfunction.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6488556     DOI: 10.1016/0009-8981(84)90014-7

Source DB:  PubMed          Journal:  Clin Chim Acta        ISSN: 0009-8981            Impact factor:   3.786


  24 in total

1.  Clinical and biochemical abnormalities in a patient with dihydropyrimidine dehydrogenase deficiency due to homozygosity for the C29R mutation.

Authors:  A B Van Kuilenburg; P Vreken; D Riva; G Botteon; N G Abeling; H D Bakker; A H Van Gennip
Journal:  J Inherit Metab Dis       Date:  1999-04       Impact factor: 4.982

2.  Metabolic approaches to the treatment of autism spectrum disorders.

Authors:  T Page
Journal:  J Autism Dev Disord       Date:  2000-10

3.  A new case of dihydropyrimidine dehydrogenase deficiency.

Authors:  M Brockstedt; C Jakobs; L M Smit; A H van Gennip; R Berger
Journal:  J Inherit Metab Dis       Date:  1990       Impact factor: 4.982

4.  The first prenatal diagnosis of dihydropyrimidine dehydrogenase deficiency.

Authors:  C Jakobs; F Stellaard; L M Smit; J M van Vugt; M Duran; R Berger; P Rovers
Journal:  Eur J Pediatr       Date:  1991-02       Impact factor: 3.183

5.  Molecular basis of the human dihydropyrimidine dehydrogenase deficiency and 5-fluorouracil toxicity.

Authors:  X Wei; H L McLeod; J McMurrough; F J Gonzalez; P Fernandez-Salguero
Journal:  J Clin Invest       Date:  1996-08-01       Impact factor: 14.808

6.  Developmental disorder associated with increased cellular nucleotidase activity.

Authors:  T Page; A Yu; J Fontanesi; W L Nyhan
Journal:  Proc Natl Acad Sci U S A       Date:  1997-10-14       Impact factor: 11.205

7.  Physiologically based pharmacokinetic modelling of the three-step metabolism of pyrimidine using C-uracil as an in vivo probe.

Authors:  Suminobu Ito; Takeshi Kawamura; Makoto Inada; Yoshiharu Inoue; Yukihiro Hirao; Toshihisa Koga; Jun-ichi Kunizaki; Takefumi Shimizu; Hitoshi Sato
Journal:  Br J Clin Pharmacol       Date:  2005-12       Impact factor: 4.335

Review 8.  Molecular basis of polymorphic drug metabolism.

Authors:  A K Daly
Journal:  J Mol Med (Berl)       Date:  1995-11       Impact factor: 4.599

Review 9.  Inherited defects of purine and pyrimidine metabolism: laboratory methods for diagnosis.

Authors:  M Duran; L Dorland; E E Meuleman; P Allers; R Berger
Journal:  J Inherit Metab Dis       Date:  1997-06       Impact factor: 4.982

10.  Identification of novel point mutations in the dihydropyrimidine dehydrogenase gene.

Authors:  P Vreken; A B Van Kuilenburg; R Meinsma; A H van Gennip
Journal:  J Inherit Metab Dis       Date:  1997-07       Impact factor: 4.982

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.